Crinetics Pharmaceuticals Inc. Insider Trading

CRNX

Last 12 months

Insiders sold $6.3M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Jun 2023.

Net open-market

−$6.3M

0 buys · 11 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 8

executives and directors

Last open-market buy

Jun 2023

Jun 8, 2023

Get an email when CRNX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jul 2	Coelho Rogerio Vivaldi Director	Sold10b5-1 plan	3,000	$40.00	120K	13%	Form 4
Jun 17	Stephanie Okey Director	Sold10b5-1 plan 2 parts	6,900	$35.67 average	246K	52%	Form 4
Apr 8	Jeff E. Knight Chief Dev. & Operating Officer	Sold10b5-1 plan	85,163	$40.10	$3.42M	45%	Form 4
Mar 16	Jeff E. Knight Chief Operating Officer	Sold10b5-1 plan 2 parts	9,911	$37.37 average	370K	8.1%	Form 4
Mar 16	Stephen F. Betz Chief Scientific Officer	Sold10b5-1 plan 2 parts	10,612	$37.37 average	397K	7.2%	Form 4
Mar 16	Richard Scott Struthers President & CEO	Sold10b5-1 plan 2 parts	21,981	$37.37 average	822K	1.6%	Form 4
Mar 12	Coelho Rogerio Vivaldi Director	Sold10b5-1 plan 2 parts	5,000	$36.15 average	181K	23%	Form 4
Mar 3	Stephanie Okey Director	Sold10b5-1 plan	3,000	$39.67	119K	18%	Form 4
Mar 3	Tobin Schilke Chief Financial Officer	Sold10b5-1 plan	6,713	$39.67	266K	7.9%	Form 4
Jan 5	Isabel Kalofonos Chief Commercial Officer	Sold10b5-1 plan	2,500	$55.00	138K	75%	Form 4
Dec 1, 2025	Dana Pizzuti Chief Med and Dev Officer	Sold10b5-1 plan	5,000	$45.02	225K	7.0%	Form 4
Nov 3, 2025	Dana Pizzuti Chief Med and Dev Officer	Sold10b5-1 plan 2 parts	5,000	$42.66 average	213K	7.0%	Form 4
Oct 1, 2025	Dana Pizzuti Chief Med and Dev Officer	Sold10b5-1 plan	5,000	$41.81	209K	7.0%	Form 4
Sep 26, 2025	Richard Scott Struthers President & CEO	Sold10b5-1 plan	4,000	$45.00	180K	0.3%	Form 4
Sep 26, 2025	Matthew K Fust Director	Sold10b5-1 plan	16,000	$44.75	716K	41%	Form 4
Sep 2, 2025	Dana Pizzuti Chief Med and Dev Officer	Sold10b5-1 plan	5,000	$32.10	161K	4.9%	Form 4
Aug 22, 2025	Dana Pizzuti Chief Med and Dev Officer	Sold10b5-1 plan	30,000	$30.43	913K	31%	Form 4
Aug 20, 2025	Dana Pizzuti Chief Med and Dev Officer	Sold10b5-1 plan	6,492	$29.18	189K	8.9%	Form 4
Jun 12, 2025	Stephen F. Betz Chief Scientific Officer	Sold10b5-1 plan	97,483	$32.23	$3.14M	49%	Form 4
Mar 19, 2025	Dana Pizzuti Chief Med and Dev Officer	Sold10b5-1 plan 2 parts	2,515	$34.20 average	86K	3.4%	Form 4
Mar 19, 2025	Jeff E. Knight Chief Operating Officer	Sold10b5-1 plan 2 parts	7,162	$34.20 average	245K	7.6%	Form 4
Mar 19, 2025	Stephen F. Betz Chief Scientific Officer	Sold10b5-1 plan 2 parts	5,770	$34.20 average	197K	5.0%	Form 4
Mar 19, 2025	Richard Scott Struthers President & CEO	Sold10b5-1 plan 2 parts	17,338	$34.20 average	593K	1.4%	Form 4
Feb 3, 2025	Dana Pizzuti Chief Med and Dev Officer	Sold10b5-1 plan	5,000	$39.07	195K	14%	Form 4
Jan 3, 2025	Dana Pizzuti Chief Med and Dev Officer	Sold10b5-1 plan	15,000	$52.09	781K	32%	Form 4
Dec 2, 2024	Richard Scott Struthers President & CEO	Sold10b5-1 plan	10,000	$57.57	576K	0.9%	Form 4
Nov 22, 2024	Jeff E. Knight Chief Operating Officer	Sold10b5-1 plan	501	$56.52	28K	1.0%	Form 4

Jul 210b5-1 plan
Coelho Rogerio Vivaldi
Director · sold 3,000 at $40.00
120K
13% of stake
Jun 1710b5-1 plan
Stephanie Okey
Director · sold 6,900 at avg $35.67
246K
52% of stake
Apr 810b5-1 plan
Jeff E. Knight
Chief Dev. & Operating Officer · sold 85,163 at $40.10
$3.42M
45% of stake
Mar 1610b5-1 plan
Jeff E. Knight
Chief Operating Officer · sold 9,911 at avg $37.37
370K
8.1% of stake
Mar 1610b5-1 plan
Stephen F. Betz
Chief Scientific Officer · sold 10,612 at avg $37.37
397K
7.2% of stake
Mar 1610b5-1 plan
Richard Scott Struthers
President & CEO · sold 21,981 at avg $37.37
822K
1.6% of stake
Mar 1210b5-1 plan
Coelho Rogerio Vivaldi
Director · sold 5,000 at avg $36.15
181K
23% of stake
Mar 310b5-1 plan
Stephanie Okey
Director · sold 3,000 at $39.67
119K
18% of stake
Mar 310b5-1 plan
Tobin Schilke
Chief Financial Officer · sold 6,713 at $39.67
266K
7.9% of stake
Jan 510b5-1 plan
Isabel Kalofonos
Chief Commercial Officer · sold 2,500 at $55.00
138K
75% of stake
Dec 1, 202510b5-1 plan
Dana Pizzuti
Chief Med and Dev Officer · sold 5,000 at $45.02
225K
7.0% of stake
Nov 3, 202510b5-1 plan
Dana Pizzuti
Chief Med and Dev Officer · sold 5,000 at avg $42.66
213K
7.0% of stake
Oct 1, 202510b5-1 plan
Dana Pizzuti
Chief Med and Dev Officer · sold 5,000 at $41.81
209K
7.0% of stake
Sep 26, 202510b5-1 plan
Richard Scott Struthers
President & CEO · sold 4,000 at $45.00
180K
0.3% of stake
Sep 26, 202510b5-1 plan
Matthew K Fust
Director · sold 16,000 at $44.75
716K
41% of stake
Sep 2, 202510b5-1 plan
Dana Pizzuti
Chief Med and Dev Officer · sold 5,000 at $32.10
161K
4.9% of stake
Aug 22, 202510b5-1 plan
Dana Pizzuti
Chief Med and Dev Officer · sold 30,000 at $30.43
913K
31% of stake
Aug 20, 202510b5-1 plan
Dana Pizzuti
Chief Med and Dev Officer · sold 6,492 at $29.18
189K
8.9% of stake
Jun 12, 202510b5-1 plan
Stephen F. Betz
Chief Scientific Officer · sold 97,483 at $32.23
$3.14M
49% of stake
Mar 19, 202510b5-1 plan
Dana Pizzuti
Chief Med and Dev Officer · sold 2,515 at avg $34.20
86K
3.4% of stake
Mar 19, 202510b5-1 plan
Jeff E. Knight
Chief Operating Officer · sold 7,162 at avg $34.20
245K
7.6% of stake
Mar 19, 202510b5-1 plan
Stephen F. Betz
Chief Scientific Officer · sold 5,770 at avg $34.20
197K
5.0% of stake
Mar 19, 202510b5-1 plan
Richard Scott Struthers
President & CEO · sold 17,338 at avg $34.20
593K
1.4% of stake
Feb 3, 202510b5-1 plan
Dana Pizzuti
Chief Med and Dev Officer · sold 5,000 at $39.07
195K
14% of stake
Jan 3, 202510b5-1 plan
Dana Pizzuti
Chief Med and Dev Officer · sold 15,000 at $52.09
781K
32% of stake
Dec 2, 202410b5-1 plan
Richard Scott Struthers
President & CEO · sold 10,000 at $57.57
576K
0.9% of stake
Nov 22, 202410b5-1 plan
Jeff E. Knight
Chief Operating Officer · sold 501 at $56.52
28K
1.0% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch CRNX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with CRNX

CompareIntrinsic value

CPIXCumberland Pharmaceuticals Inc.

$4.44+3.02%13

WVEWave Life Sciences Ltd.

$3.62+1.12%40

BFRIBiofrontera Inc.

$0.90+1.55%30

CELUCelularity Inc.

$0.81-1.00%0

VRCAVerrica Pharmaceuticals Inc.

$3.46+5.02%40

LIFDLftd Partners Inc.

$0.11+0.00%35

VTVTvTv Therapeutics Inc.

$24.03+2.04%40

NRIXNurix Therapeutics Inc.

$15.95-38.23%84

Held by ETFs

CRNX is in 31 US ETFs. The largest of them, with CRNX's weight in each:

Spot a number that looks wrong? Check it in CRNX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CRNX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.